Additionally, individuals should be aware that: Retatrutide is not licensed in the UK, meaning its full risk profile is still being established Testosterone is a controlled drug in the UK under the Misuse of Drugs Act 1971 when obtained without a valid prescription [11] [12] Any combination therapy should be documented, monitored, and reviewed regularly by a specialist Current MHRA and Clinical Guidance on Combining These Drugs Neither the MHRA nor NICE has issued specific guidance on combining retatrutide and testosterone
Medvidovic-Grubisic M, Stambolija V, Kolenc D, Katancic J, Murselovic T, Plestina-Borjan I, et al
Biological and pharmacological aspects of the NK1-receptor
Munro and Livingston 2012)
Typical histopathological features of the disease include myocyte disorganization and changes in myocardial fibrosis (72)
The discomfort is typically minimal and brief